Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Apremilast

Brand: Otezla¬ģ
NICE TA: 433
Indication: Active psoriatic arthritis (NICE TA433)
Disease category: Musculoskeletal system
Commissioning responsibility: CCG
PbR excluded: Yes

Background

Apremilast, alone or in combination with disease-modifying antirheumatic
drugs (DMARDs), is recommended as an option for treating active psoriatic
arthritis in adults only if:
1. they have peripheral arthritis with 3 or more tender joints and 3 or more swollen joints and
2. their disease has not responded to adequate trials of at least 2 standard DMARDs, given either alone or in combination and
3. the company provides apremilast with the discount agreed in the patient access scheme.
Stop apremilast at 16 weeks if the psoriatic arthritis has not shown an
adequate response using the Psoriatic Arthritis response Criteria (PsARC),
defined as an improvement in at least 2 of the 4 PsARC criteria (including joint tenderness or swelling score) with no worsening in any criteria. If the disease has a Psoriasis Area and Severity Index (PASI) 75 response, a dermatologist should decide whether to continue treatment with apremilast after 16 weeks based on skin response.

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red